Notice to Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf

Core Viewpoint - Grabar Law Office is investigating potential breaches of fiduciary duties by the Board of Directors of Integra LifeSciences Holdings Corp. [1] Group 1: Shareholder Actions - Current shareholders who held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms and the return of funds spent on litigation [2][4] - Shareholders can also pursue a court-approved incentive award at no cost [2][4] Group 2: Securities Fraud Allegations - A securities fraud class action complaint alleges that Integra's officers and directors misrepresented the company's growth prospects for SurgiMend, claiming FDA approval for post-mastectomy reconstruction [3] - On May 23, 2023, Integra announced a recall of all products manufactured at its Boston Facility from March 1, 2018, to May 22, 2023, due to deviations from good manufacturing practices [3] - The recall was attributed to unsafe levels of bacterial endotoxins in products, leading to a revised revenue guidance for Q2 2023 and an expected $22 million impairment from inventory write-off [3]